Energotropic agents are important to prevent urinary tract infections in children
G.M. Letifov1, E.P. Krivonosova1, F.Kh. Ausheva2
1Rostov State Medical University, Rostov-on-Don, Russian Federation
2Republican Clinical Perinatal Center, Nazran, Russian Federation
Aim: to provide pathogenic basis for the efficacy of levocarnitine (Elcar®), energotropic agent, in infants and young children to prevent urinary tract infections.
Patients and Methods: 50 full-term at-risk infants in the first 5 days of life who were followed up to 3 years (20 boys and 30 girls) born from mothers with anemia stage 2–3 and vegetative dysfunction as well 30 age-matched healthy children (10 boys and 20 girls) were enrolled in the study. At-risk children were divided into 2 subgroups. In subgroup A (n=21), complex basis prophylaxis (i.e., sanation of chronic infections, prevention of microbiota disorders, vitamin therapy) was performed. In subgroup B (n=29), 30% Elcar® (2–3 drops twice daily in infants and 4 drops thrice daily in children under 3 years old) was prescribed in addition to the complex basis prophylaxis. Children received this therapy every year for 2 courses lasting 1 month for 3 years. Kidney sizes and renal blood flow were evaluated in the first 5 days of life and every 6 months up to 3 years. Free radical oxidation system was assessed by serum chemiluminescence of luminol-Н2О2 system.
Results: in subgroup A, blood chemiluminescence, i.e., the height of rapid flash (Н=60.14±3.33 mm) and light sum (Sm=460.7±27.41 relative units × 104), reduced in catamnesis (p<0.01 and p<0.001, respectively) but did not achieve the levels in healthy children in 76% of cases. In subgroup B, blood chemiluminescence parameters were similar to these ones in the control group (Н=47.76±2.73 mm, Sm=376.5±18.0 relative units × 104; p>0.05).
Conclusion: in at-risk infants, kidney growth delay and poor renal blood flow were demonstrated as compared with healthy children. Elcar® improves renal blood flow in 75% of cases and kidney growth in 80% of cases.
Keywords: children, infants, urinary tract infections, oxidative stress, energotropic agents, levocarnitine, Elcar.
For citation: Letifov G.M., Krivonosova E.P., Ausheva F.Kh. Energotropic agents are important to prevent urinary tract infections in children. Russian Journal of Woman and Child Health. 2019;2(4):340–345.
About the authors:
1Gadzhi M. Letifov — MD, PhD, Professor, Head of the Department of Pediatrics and Neonatology, ORCID iD 0000-0002-5094-7599;
1Ekaterina P. Krivonosova — MD, PhD, Assistant of the Department of Pediatrics and Neonatology, ORCID iD 0000-0002-4090-3728;
2Fatima Kh. Ausheva — MD, PhD, Deputy Head Doctor for Pediatrics, ORCID iD 0000-0001-8928-5644.
1Rostov State Medical University. 29, Nakhichevanskiy lane, Rostov-on-Don, 344022, Russian Federation.
2Republican Clinical Perinatal Center. 79, Bakinskaya str., Nazran, 368140, Russian Federation.
Contact information: Gadzhi M. Letifov, e-mail: email@example.com.
Financial Disclosure: no author has a financial or property interest in any material or method mentioned. There is no conflict of interests. Received 11.08.2019.
2. Gruba V.F., Letifov G.M., Ausheva F. Kh., Belikova E.E. Perinatal risk factors for the formation of premorbid background of urinary tract infection in children. Meditsinskiy vestnik Yuga Rossii (Appendix). 2012:23–24 (in Russ.).
3. Infections of the urinary system in children: A guide for doctors. Ed. V.V. Dlin, I.M. Osmanov, O.L. Chugunova. M.: Overlay; 2017 (in Russ).
4. Letifov G.M., Krivonosova E.P., Belikova E.E., Ausheva F.H. Harmony in the system of free radical oxidation and antioxidant protection as a predictor of infection persistence and progression of pyelonephritis in children. Orenburgskiy meditsinskiy vestnik (Appendix). 2017;3(19):35–37 (in Russ.).
5. Neudakhin E.V. Pathogenetic justification of the use of energotropic drugs in diseases of the urinary system in children. Pediatriya. Prilozheniye k zhurnalu Consilium Medicum. 2018;2:32–37 (in Russ.). DOI: 10.26442/2413-8460_2018.2.68-73.
6. Brin I.L., Neudakhin E.V., Dunaikin M.L. Carnitine in Pediatrics: research and clinical practice. M.: Medpraktika-M; 2015 (in Russ.).
7. Chugunova O.L., Dumova S.V., Foktova A.S. et al. Criteria for early diagnosis of acute renal damage in deeply premature infants and the possibility of therapeutic correction. Pediatriya im. G.N. Speranskogo. 2015;94(3):8–12 (in Russ.).
8. Neudakhin E.V. Expediency of using carnitine preparations in the treatment of chronic eating disorders in children. Praktika pediatra. 2015;2:48–52 (in Russ.).
9. Ivanova I.I., Gnusaev S.F., Sukhorukov V.S. et al. Manifestations of mitochondrial dysfunction in children with connective tissue dysplasia and chronic gastroduodenitis. Rossiyskiy vestnik perinatologii i pediatrii. 2019;64(5):84–90 (in Russ.).
10. Morozov S.L, Dlin V.V. The state of cellular bioenergy in children with an overactive bladder. The effectiveness of energy-stimulating therapy. RMJ. 2016;15:1–6 (in Russ.).
11. Chugunova O.L., Shumikhina M.V., Dumova S.V., Foktova A.S. Features of the pathogenesis, diagnosis, course of infections of the urinary system in newborns and young children, the possibility of therapeutic correction. Vestnik sovremennoy klinicheskoy meditsiny. 2013;6(6):119–128 (in Russ.).
This work is licensed under a Creative Commons «Attribution» 4.0 License.